Lipoprotein-genotype associations in Trinidadian neonates

Clinical Biochemistry

Volumn 32, Issue 6, 1999, Pages 429-437

  Hegele, Robert A ^a   Ban, Matthew R ^a   Busch, Christopher P ^a   Ramsewak, Samuel ^b   Ramdath, D Dan ^b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

Author keywords

Aging; Candidate genes; Hyperlipidemia; Oxidation

Indexed keywords

ANGIOTENSINOGEN; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; BETA 3 ADRENERGIC RECEPTOR; FATTY ACID BINDING PROTEIN; HELICASE; LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE;

AGING; ARTICLE; BIRTH WEIGHT; CHROMOSOMAL LOCALIZATION; DISEASE ASSOCIATION; ETHNOLOGY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; NEWBORN; OXIDATION; PRIORITY JOURNAL;

AFRICA; AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; ANGIOTENSINOGEN; APOLIPOPROTEINS E; ARYLDIALKYLPHOSPHATASE; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; CARRIER PROTEINS; DNA HELICASES; ESTERASES; FATTY ACID-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENETICS, POPULATION; HUMANS; INFANT, NEWBORN; LIPASE; LIPOPROTEINS; MALE; MYELIN P2 PROTEIN; NEOPLASM PROTEINS; PHENOTYPE; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, ADRENERGIC, BETA-3; RECQ HELICASES; TRINIDAD AND TOBAGO; TUMOR SUPPRESSOR PROTEINS; VARIATION (GENETICS);

EID: 0032725171     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(99)00035-1     Document Type: Article

References (82)

1. Natural history of aortic and coronary atherosclerotic lesions in youth findings from the PDAY study . Arterioscler Thromb. 13:1993;1291-1298.
2. Kwiterowich P.O. Jr. Dyslipoproteinemia and other risk factors for atherosclerosis in children and adolescents. Atherosclerosis. 108:1994;S55-S71.
3. Strong J.P. Natural history and risk factors for early human atherogenesis. Pathobiological Determinants of atherosclerosis in youth (PDAY) research group. Clin Chem. 41:1995;134-138.
4. Kaprio J., Norio R., Pesonen E., Sarna S. Intimal thickening of the coronary arteries in infants in relation to family history of coronary artery disease. Circulation. 87:1993;1960-1968.
5. Tracy R.E., Newman W.P. III, Wattigney W.A., Berenson G.S. Risk factors and atherosclerosis in youth autopsy findings of the Bogalusa heart study. Am J Med Sci. 310:1995;S37-S41.
6. Berenson G.S., Srinivasan S.R., Bao W., Newman W.P. III, Tracy R.E., Wattigney W.A. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 338:1998;1650-1656.
7. Breslow J.L. Genetic basis of lipoprotein disorders. J Clin Invest. 84:1989;373-380.
8. Mehrabian M., Lusis A.J. Genetic markers for atherosclerosis and related risk factors. Lusis A.J., Rotter J.I., Sparkes R.S. Molecular Genetics of Coronary Artery Disease Candidate Genes and Processes in Atherosclerosis . 1992;363-418 Karger, Basel.
9. Hegele R.A. The pathogenesis of atherosclerosis. Clin Chim Acta. 246:1996;21-38.
10. Hegele R.A. Candidate genes, small effects, and the prediction of atherosclerosis. Crit Rev Clin Lab Sci. 34:1997;343-367.
11. Lander E.S., Schork N.J. Genetic dissection of complex traits. Science. 265:1994;2037-2048.
12. Sing C.F., Davignon J. Role of apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet. 37:1985;268-285.
13. Walston J., Silver K., Bogardus C., et al. Time of onset of non-insulin dependent diabetes mellitus and genetic variation in the beta-3-adrenergic receptor gene. N Engl J Med. 333:1995;343-347.
14. Widen E., Lehto M., Kanninen T., Walston J., Shuldiner A.R., Groop L.C. Association of a polymorphism in the beta-3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med. 333:1995;348-351.
15. Clement K., Vaisse C., Manning B.S.J., et al. Genetic variation in the beta-3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med. 333:1995;352-354.
16. Silver K., Walston J., Wang Y., Dowse G., Zimmet P., Shuldiner A.R. Molecular scanning for mutations in the beta-3-adrenergic receptor gene in Nauruans with obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 81:1996;4155-4158.
17. Kurabayashi T., Carey D.G., Morrison N.A. The beta-3-adrenergic receptor gene Trp64Arg mutation is over-represented in obese women. Diabetes. 45:1996;1358-1363.
18. Gagnon J., Mauriege P., Roy S., et al. The Trp64Arg mutation of the beta-3-adrenergic receptor gene has no effect on obesity phenotypes in the Quebec Family Study and Swedish Obese Subjects cohorts. J Clin Invest. 98:1996;2086-2093.
19. Elbein S.C., Hoffman M., Barrett K., et al. Role of the beta-3-adrenergic receptor locus in obesity and noninsulin-dependent diabetes among members of caucasian families with a diabetic sibling pair. J Clin Endocrinol Metab. 81:1996;4422-4427.
20. Clement K., Ruiz J., Cassard-Doulcier A.-M., et al. Additive effect of a A-G (-3826) variant of the uncoupling protein gene and the Trp64Arg mutation of the beta-3-adrenergic receptor gene on weight gain in morbid obesity. lnt J Obes. 20:1996;1062-1066.
21. Fumeron F., Durack-Bown I., Betoulle D., et al. Polymorphisms of uncoupling protein (UCP) and beta-3 adrenoreceptor genes in obese people submitted to a low calorie diet. Int J Obes. 20:1996;1051-1054.
22. Zhang Y., Watt N., Stratton I.M., et al. UKPDS 19 heterogeneity in NIDDM: separate contributions of IRS-1 and beta-3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations . Diabetologia. 39:1996;1505-1511.
23. Oksanen L., Mustajoki P., Kaprio J., et al. Polymorphism of the beta-3-adrenergic receptor gene in morbid obesity. Int J Obes. 20:1996;1055-1061.
24. Li L.S., Luhnqvist F., Luthman H., Arner P. Phenotypic characterization of the Trp64Arg polymorphism in the beta-3-adrenergic receptor gene in normal weight and obese subjects. Diabetologia. 39:1996;857-860.
25. Urhammer S.A., Clausen J.O., Hansen T., Pedersen O. Insulin sensitivity and body weight changes in young White carriers of the codon 64 amino acid polymorphism of the beta-3-adrenergic receptor gene. Diabetes. 45:1996;1115-1120.
26. Kadowaki H., Yasuda K., Iwamoto K., et al. A mutation in the beta-3-adrenergic receptor gene is associated with obesity and hyperinsulinaemia in Japanese subjects. Biochem Biophys Res Commun. 215:1995;555-560.
27. Fujisawa T., lkegami H., Yamato E., et al. Association of Trp64Arg mutation of the beta-3-adrenergic receptor with NIDDM and body weight gain. Diabetologia. 39:1996;349-352.
28. Yoshida T., Sakane N., Umekawa T., Sakai M., Takahashi T., Kondo M. Mutation of beta-3-adrenergic-receptor gene and response to treatment of obesity. Lancet. 346:1995;1433-1434.
29. Ueda K., Tanizawa Y., Oota Y., et al. Prevalence of the Trp64Arg missense mutation of the beta-3-adrenergic receptor gene in Japanese subjects. Metabolism. 46:1997;199-202.
30. Baier L.J., Sacchettini J.C., Knowler W.C., et al. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation and insulin resistance. J Clin Invest. 95:1995;1281-1287.
31. Mitchell B.D., Kammerer C.M., O'Connell P., et al. Evidence for linkage of postchallenge insulin levels with intestinal fatty acid binding protein (FABP2) in Mexican-Americans. Diabetes. 44:1995;1046-1053.
32. Hegele R.A., Brunt J.H., Connelly P.W. A polymorphism of the paraoxonase gene associated with variation in blood pressure in a genetic isolate. Arterioscler Thromb Vasc Biol. 15:1995;89-95.
33. Ruiz J., Blanche H., James R.W., et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346:1995;869-872.
34. Serrato M., Marrian A.J. A variant of the human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. 96:1995;3005-3008.
35. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum plasma paraoxonase activity polymorphism. Nat Genet. 3:1993;73-76.
36. Hegele R.A., Connelly P.W., Scherer S.W., et al. Paraoxonase-2 G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 82:1997;3373-3377.
37. Boright A.P., Connelly P.W., Brunt J.H., Scherer S.W., Tsui L.C., Hegele R.A. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. Atherosclerosis. 139:1998;131-136.
38. Sanghera D.K., Aston C.E., Saha N., Kamboh M.I. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet. 62:1998;36-44.
39. Heinecke J.W., Lusis A.J. Paraoxonase-gene polymorphisms associated with coronary heart disease support for the oxidative damage hypothesis? Am J Hum Genet. 62:1998;20-24.
40. Murtomaki S, Tahvanainen E, Antikainen M, et al. Hepatic lipase gene polymorphisms influence plasma HDL levels. Arterioscler Thromb Vasc Biol 1997; 17: 1879-84.
41. Guerra R., Wang J., Grundy S.M., Cohen J.C. A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci USA. 94:1997;4532-4537.
42. Jansen H., Verhoeven A.J.M., Weeks L., et al. Common C-to-T substitution at position-480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients. Arterioscler Thromb Vasc Biol. 17:1997;2837-2842.
43. Tahvanainen E., Syvanne M., Frick M.H., et al. Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene. The LOCAT Study Investigators. J Clin Invest. 101:1998;956-960.
44. Vega G.L., Clark L.T., Tang A., Marcovina S., Grundy S.M., Cohen J.C. Hepatic lipase activity is lower in African American men than in white American men effects of the 5′ flanking polymorphism in the hepatic lipase gene . J Lipid Res. 39:1998;228-232.
45. Ye L., Miki T., Nakuar J., et al. Association of a polymorphic variant of the Werner helicase gene with myocardial infarction in a Japanese population. Am J Med Genet. 68:1997;494-498.
46. More S., Yokote K., Morisaki N., Saito Y., Yoshida S. Inheritable abnormal lipoprotein metabolism in Werner's syndrome similar to familial hypercholesterolemia. Eur J Clin Invest. 20:1990;137-142.
47. Pajukanta P., Nuotio I., Terwilliger J.D., et al. Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. Nat Genet. 18:1998;369-373.
48. Beckles G.L.A., Kirkwood B.R., Carson D.C., Miller G.J., Alexis S.D., Byam N.T.A. High total and cardiovascular disease mortality in adults of Indian descent in Trinidad, unexplained by major coronary risk factors. Lancet. i:1986;1298-1301.
49. Hegele R.A., Harris S.B., Hanley A.J., Sun F., Connelly P.W., Zinman B. Angiotensinogen gene variation associated with variation in blood pressure in aboriginal Canadians. Hypertension. 29:1997;1073-1077.
50. SAS/STAT guide for personal computers. Version 6 edition. 1987;SAS Institute Inc, Cary NC.
51. Williams R.R., Hunt S.C., Hopkins P.N., Hasstedt S.J., Wu L.L., Lalouel J.M. Finding the genes for human hypertension. Woodford F.P., Davignon J., Sniderman A. Atherosclerosis X. 1994;856-861 Elsevier, Amsterdam.
52. Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., et al. Molecular basis of human hypertension role of angiotensinogen . Cell. 71:1992;169-180.
53. Bloem L.J., Manatunga A.K., Tewksbury D.A., Pratt J.H. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest. 95:1995;948-953.
54. Rotimi C., Morrison L., Cooper A., et al. Angiotensinogen gene in human hypertension lack of an association of the T235 allele among African Americans . Hypertension. 24:1994;591-594.
55. Hata A., Namikawa C., Sasaki M., et al. Angiotensinogen as a risk factor for essential hypertension in Japan. J Clin Invest. 93:1994;1285-1287.
56. Bennett C.L., Schrader A.P., Morris B.J. Cross-sectional analysis of Met235 → Thr variant of angiotensinogen gene in severe familial hypertension. Biochem Biophys Res Commun. 197:1993;833-839.
57. Caulfield M., Lavender P., Farrall M., et al. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med. 330:1994;1629-1633.
58. Ward K., Hata A., Jeunemaitre X., et al. A molecular variant of angiotensinogen associated with preeclampsia. Nat Genet. 4:1993;59-61.
59. Keidar S., Kaplan M., Shapira C., Brook J.G., Aviram M. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages a possible role for angiotensin II . Atherosclerosis. 107:1994;71-84.
60. Keidar S., Kaplan M., Aviram M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation. Arterioscler Thromb Vasc Biol. 16:1996;97-105.
61. Keidar S., Kaplan M., Hoffman A., Aviram M. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis. 115:1995;201-215.
62. Yu C.-E., Oshima J., Fu Y.-H., et al. Positional cloning of the Werner's syndrome gene. Science. 272:1996;193-194.
63. Epstein C.J., Martin G., Schultz A.L., Motilsky A.G. Werner's syndrome a review of its symptomatology, natural history, pathological features, genetics and relationship to the natural aging process . Medicine. 45:1966;177-222.
64. Gray M.D., Shen J.-C., Kamath-Loeb A.S., et al. The Werner syndrome protein is a DNA helicase. Nat Genetics. 17:1997;100-103.
65. Noma A., Abe A., Maeda S., et al. Lp(a) an acute-phase reactant? Chem Phys Lipids. 67:1994;411-417.
66. Beckles G.L.A., Kirkwood B.R., Carson D.C., Miller G.J., Alexis S.D., Byam N.T.A. High total and cardiovascular disease mortality in adults of Indian descent in Trinidad, unexplained by major coronary risk factors. Lancet. i:1986;1298-1301.
67. Ghiselli G., Gregg R.E., Zech L.A., Schaefer E.J., Brewer H.B. Jr. Phenotype study of apolipoprotein E isoforms in hyperlipoproteinaemic patients. Lancet. 21:1982;405-407.
68. Ghiselli G., Schaefer E.J., Zech L.A., Gregg R.E., Brewer H.B. Jr. Increased prevalence of apolipoprotein E4 in type V hyperlipoproteinemia. J Clin Invest. 70:1982;474-477.
69. Bioletto S., Fontana P., Darioli R., James R.W. Apolipoprotein E polymorphism and the distribution profile of very low density lipoproteins; an influence of the E4 allele on large (Sf > 60) particles. Atherosclerosis. 138:1998;207-215.
70. Evans A.J., Huff M.W., Wolfe B.M. Accumulation of an apoE-poor subfraction of very low density lipoprotein in hypertriglyceridemic men. J Lipid Res. 30:1989;1691-1701.
71. Evans A.J., Wolfe B.M., Strong W.L., Huff M.W. Reduced lipolysis of large apoE-poor very-low-density lipoprotein subfractions from type IV hypertriglyceridemic subjects in vitro and in vivo. Metabolism. 42:1993;105-115.
72. Steinmetz A., Thiemann E., Czekelius P., Kaddarnik H. Polymorphism of apolipoprotein E influences levels of serum apolipoproteins E and B in the human neonate. Eur J Clin Invest. 19:1989;390-394.
73. Lehtimaki T., Porkka K., Viikari J., Ehnholm C., Akerblom H.K., Nikkari T. Apolipoprotein E phenotypes and serum lipids in newborns and 3-year-old children the Cardiovascular Risk in Young Finns Study . Pediatrics. 94:1994;489-493.
74. Enas E.A., Yusuf S., Garg A., Davidson L., Thomas J., Pearson T.A. Lipoprotein (a) levels in Indian physicians comparisons with white and black physicians in the US . Indian Heart J. 46:1994;1.
75. Van Biervliet J.P., Labeur C., Michiels G., Usher D.C., Rosseneu M. Lipoprotein(a) profiles and evolution in newborns. Atherosclerosis. 86:1991;173-181.
76. Wang X.L., Wilcken D.E., Dudman N.P. Neonatal apo A-I, apo B, and apo(a) levels in dried blood spots in an Australian population. Pediatr Res. 28:1990;496-501.
77. Merzouk H., Meghelli-Bouchenak M., el-Korso N., Belleville J., Prost J. Low birth weight at term impairs cord serum lipoprotein compositions and concentrations. Eur J Pediatr. 157:1998;321-326.
78. Morillas J.M., Molto L., Robles R., Gil A., Sanchez-Pozo A. Lipoproteins in preterm and small-for-gestational-age infants during the first week of life. Acta Paediatr. 81:1992;774-778.
79. Bastida S., Sanchez-Muniz F.J., Cuesta C., Perea S., Ureta A. Serum apolipoproteins A-I and B in male and female full-term newborns of the Toledo study (Spain). Acta Paediatr. 85:1996;750-752.
80. Morlese J.F., Jahoor F., Forrester T.E. Plasma apolipoprotein A1 and birthweight. Lancet. 350:1997;1823-1824.
81. Van Biervliet J.P., Vercaemst R., De Keersgieter W., Vinaimont N., Caster H., Rosseneu M. Evolution of lipoprotein patterns in newborns. Acta Paediatr Scand. 69:1980;593-596.
82. Low P.S., Saha N., Tay J.S., Arulkumaran S. Influence of PvuII (intron 6) polymorphism of the lipoprotein lipase gene on cord plasma lipid and apolipoprotein levels in Indian and Chinese newborns of Singapore. Pediatr Res. 43:1998;240-244.